產(chǎn)品名稱 |
443-15D3-2F12 [15D3, CMCC 10748] |
商品貨號 |
B163747 |
Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
Cell Type |
hybridoma: B lymphocyte |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Strain |
Strain: BALB/c (B cell); BALB/c (myeloma) |
Applications |
Animals were immunized with BALB/c 3T3 fibroblast cells, which were transfected with the human MDR1 gene and then selected for the drug resistance phenotype by growth in vinblastine-containing culture medium. The antibody may be useful for diagnostic detection of MDR in patients undergoing chemotherapy or as targeting components of immunotherapeutic agents. |
Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
Derivation |
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. |
Clinical Data |
The antibody may be useful for diagnostic detection of MDR in patients undergoing chemotherapy or as targeting components of immunotherapeutic agents. |
Genes Expressed |
immunoglobulin; monoclonal antibody; against the human multi-drug resistance antigen, P-glycoprotein |
Cellular Products |
immunoglobulin; monoclonal antibody; against the human multi-drug resistance antigen, P-glycoprotein |
Comments |
Animals were immunized with BALB/c 3T3 fibroblast cells, which were transfected with the human MDR1 gene and then selected for the drug resistance phenotype by growth in vinblastine-containing culture medium. Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. The murine hybridoma 15D3 recognizes the human multi-drug resistance antigen, P-glycoprotein. The antibody immunoprecipitates a 170- to 180-kDa protein from multi-drug resistance (MDR) cells, but does not block binding of the known anti-P-glycoprotein antibody MRK16. The antibody may be useful for diagnostic detection of MDR in patients undergoing chemotherapy or as targeting components of immunotherapeutic agents. The hybrid hybridoma cell lines 1B7 (ATCC HB-10500) and 1A7 (ATCC HB-10501) were formed by the fusion of the 15D3 (ATCC HB-11342) and 3G8 hybridoma cell lines. |
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
Subculturing |
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
Cryopreservation |
culture medium 95%; DMSO, 5% |
Culture Conditions |
Temperature: 37.0°C |
Isotype |
IgG1; kappa light chain |
Name of Depositor |
Chiron Corp. |
Deposited As |
mouse (B cell); mouse (myeloma) |
U.S. Patent Number |
|
References |
Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000
Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999
Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000
Ring DB. Nucleic acids encoding antigen-binding sites specific for cancer antigens. US Patent 5,948,647 dated Sep 7 1999
Ring DB. Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer. US Patent 5,811,267 dated Sep 22 1998
Shi T, et al. High-affinity monoclonal antibodies against P-glycoprotein. Clin. Immunol. Immunopathol. 76: 44-51, 1995. PubMed: 7541735
|